2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14538S
    Haloperidol-d4 1189986-59-1 98%
    Haloperidol-d4 is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.
    Haloperidol-d4
  • HY-145454
    (R)-Preclamol 85976-54-1 99.56%
    (R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses.
    (R)-Preclamol
  • HY-145459
    N-Boc Ketamine 1461707-29-8
    N-Boc Ketamine is an arylcyclohexylamine.
    N-Boc Ketamine
  • HY-145466
    EVT-401 99.89%
    EVT-401 (P2X7 receptor antagonist-1) is a purinergic P2X7 receptor antagonist. EVT-401 has efficacy of combating neuroinflammation.
    EVT-401
  • HY-145486
    1-Arachidonoyl-sn-glycerol 3-phosphate ammonium 799268-65-8 98%
    1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD).
    1-Arachidonoyl-sn-glycerol 3-phosphate ammonium
  • HY-145519
    Mu-6S-Palm-β-Glc 229644-17-1 99.9%
    Mu-6S-Palm-β-Glc is a fluorogenic substrate for palmitoyl-protein thioesterase (PPT). Mu-6S-Palm-β-Glc can be used for the research of neuronal ceroid lipofuscin disease in infants.
    Mu-6S-Palm-β-Glc
  • HY-14566A
    (S)-Donepezil 142057-80-5 98%
    (S)-Donepezil is a S-enantiomer of Donepezil (HY-14566). Donepezil is a specific and potent AChE inhibitor.
    (S)-Donepezil
  • HY-14595R
    Biochanin A (Standard) 491-80-5 98.74%
    Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC50s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.
    Biochanin A (Standard)
  • HY-146958
    MAO-B-IN-8 1638956-60-1 98.03%
    MAO-B-IN-8 is a potent reversible MAO-B inhibitor and an inhibitor of microglial production of neuroinflammatory mediator. MAO-B-IN-8 can be used for neurodegenerative disease research.
    MAO-B-IN-8
  • HY-147233
    MIND4-19 129544-85-0 99.93%
    MIND4-19 is a potent SIRT2 inhibitor with an IC50 value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease.
    MIND4-19
  • HY-147638
    MONIRO-1 1909225-94-0 99.18%
    MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively. MONIRO-1 has low activity against L-type calcium channels. MONIRO-1 can be used for the study of pain and epilepsy.
    MONIRO-1
  • HY-14763S
    Cariprazine-d6 1308278-67-2 98.74%
    Cariprazine-d6 is a deuterium labeled Cariprazine. Cariprazine Cariprazine is an antipsychotic agent that exhibits high affinity for the D3 (Ki of 0.085 nM) and D2 (Ki of 0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki of 2.6 nM).
    Cariprazine-d6
  • HY-14778A
    (S)-Retosiban 2994298-20-1 99.12%
    (S)-Retosiban is the isomer of Retosiban (HY-14778), and can be used as an experimental control. Retosiban (GSK221149A) is a potent and selective oxytocin antagonist with a Ki of 0.65 nM.
    (S)-Retosiban
  • HY-14785A
    Befiradol hydrochloride 2436760-81-3 99.93%
    Befiradol hydrochloride (NLX-112 hydrochloride) is a selective 5-HT1A receptor agonist.
    Befiradol hydrochloride
  • HY-147976
    Glucocerebrosidase-IN-1 2279945-76-3 98%
    Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD).
    Glucocerebrosidase-IN-1
  • HY-148112
    Casein kinase 1δ-IN-1 851871-94-8 99.91%
    Casein kinase 1δ-IN-1 is an inhibitor of casein kinase 1δ (CK1δ). Casein kinase 1δ-IN-1 can be used for the research of neurodegenerative diseases such as tauopathies.
    Casein kinase 1δ-IN-1
  • HY-148132
    GSK-3β inhibitor 11 536731-65-4 98.02%
    GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research.
    GSK-3β inhibitor 11
  • HY-148135
    hCAI/II-IN-6 694466-00-7 98.0%
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
    hCAI/II-IN-6
  • HY-148179
    Neuropeptide Y5 receptor ligand-1 322723-35-3 98.0%
    Neuropeptide Y5 receptor ligand-1 (compound 54), a carbazole derivative, is a potent neuropeptide Y5 (NPY-5) receptor antagonist.
    Neuropeptide Y5 receptor ligand-1
  • HY-148187
    NLRP3-IN-11 2769040-91-5 98.79%
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases.
    NLRP3-IN-11
Cat. No. Product Name / Synonyms Application Reactivity